TTK Healthcare Limited , a prominent player in the healthcare sector, has reported a mixed set of financial results for the second quarter of the fiscal year. The company saw an increase in net profit but faced challenges in terms of EBITDA performance.

Key Financial Highlights

Profit Growth Amidst Challenges

TTK Healthcare demonstrated resilience in its bottom line, reporting a net profit of ₹204.00 crore for Q2, up from ₹172.00 crore in the same period last year, marking an 18.60% increase. This growth in profit is particularly noteworthy given the challenging operating environment.

Revenue Performance

The company's revenue saw a marginal increase, growing to ₹2,000.00 crore from ₹1,980.00 crore year-over-year. This modest 1.00% growth suggests a relatively stable demand for the company's products and services in the market.

EBITDA and Margin Pressure

Despite the growth in revenue and net profit, TTK Healthcare faced significant pressure on its operational efficiency. The EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) declined to ₹53.30 crore from ₹82.30 crore in the previous year. This represents a substantial decrease of 35.20%.

More concerning is the compression in the EBITDA margin, which fell to 2.62% from 4.15% in the same quarter last year. This 153 basis points reduction in margin indicates increased operational costs or pricing pressures in the market.

Analysis and Outlook

The divergence between net profit growth and EBITDA decline suggests that TTK Healthcare might have benefited from non-operational factors such as lower tax outgo or exceptional items. The company's ability to maintain profit growth despite margin pressures demonstrates effective cost management in other areas.

However, the significant drop in EBITDA and margin compression warrants attention. It may indicate rising input costs, increased competition, or challenges in pricing power. The management may need to focus on operational efficiency and cost control measures to improve margins in the coming quarters.

As TTK Healthcare navigates through these mixed results, investors and analysts will be keen to see how the company addresses the operational challenges while maintaining its profit growth trajectory in the future quarters.

TTK Healthcare Limited has announced the unexpected demise of Mr. T T Venkatesh, a member of the company's Promoter and Promoter Group, on September 17, 2025. The company expressed deep sorrow and condolences to his family in a regulatory filing.

Shareholding Details

Mr. Venkatesh held a significant position within the company's ownership structure:

Impact on Promoter Group

Following Mr. Venkatesh's passing, the company has informed that he will cease to be part of the Promoter and Promoter Group, in accordance with Regulation 31A(6)(c) of the SEBI LODR Regulations, 2015. However, his name will remain in the company's shareholding pattern until the transmission of his shares to his nominees is completed.

Corporate Governance Update

In a separate announcement, TTK Healthcare Limited also disclosed that it has complied with SEBI's recent circular on the 'Ease of Doing Investment.' The company has published information in Business Standard (English Version) across four editions on September 16, 2025, regarding the opening of a special window for re-lodgement of transfer requests for physical shares. This information has also been made available on the company's website and LinkedIn page, demonstrating TTK Healthcare's commitment to transparency and adherence to regulatory requirements.

The passing of Mr. T T Venkatesh marks a significant change in the company's promoter group composition. Stakeholders and investors will be watching closely for any potential impacts on the company's governance and ownership structure in the coming days.